LLY

Three blue-chip companies—Apple, Eli Lilly, and Coca-Cola—have reached new 52-week highs, demonstrating strong relative performance amid market volatility. Apple benefits from iPhone momentum and AI opportunities, Eli Lilly capitalizes on booming obesity and diabetes treatments, while Coca-Cola offers defensive stability with consistent dividend growth.

The article highlights two non-AI healthcare growth stocks worth holding for the next decade: Axsome Therapeutics, a biotech company with promising pipeline expansion including Auvelity's label expansion into Alzheimer's treatment, and Eli Lilly, which dominates the weight loss and diabetes markets with strong revenue and earnings growth. Both companies are positioned to deliver solid long-term returns through patent protection and diversified product pipelines.

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

The article compares Novo Nordisk (NVO) and Viking Therapeutics (VKTX) as investment opportunities in the growing obesity-treatment market projected to reach $114 billion by 2030. NVO has established products like Wegovy and Ozempic but faces intensifying competition from Eli Lilly's tirzepatide drugs.

VKTX, a clinical-stage biotech, is advancing VK2735 in phase III studies with promising maintenance data showing 90% weight-loss retention with biweekly dosing. While NVO offers stability with declining earnings, VKTX presents higher-risk, higher-reward potential with a Zacks Rank #2 (Buy) versus NVO's #3 (Hold).

Novo Nordisk's Q3 2026 results will focus on Ozempic and Wegovy sales, which represent 75.5% of H1 adjusted sales. The company faces pricing pressure, weaker injectable GLP-1 prescription trends, and intensifying competition from Eli Lilly's tirzepatide drugs. Novo's oral semaglutide pills (Wegovy and Ozempic tablets) show strong early uptake, but overall 2026 guidance remains flat to -6% at constant exchange rates.

Eli Lilly (LLY) has gained 9.7% over the past month, outperforming the S&P 500. The company shows strong revenue growth of 36.5% for the current fiscal year and has consistently beaten earnings and revenue estimates. However, the stock is trading at a premium valuation (Value Style Score D) and carries a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

Novo Nordisk announced Phase 3 trial results for CagriSema, its next-generation obesity drug combining semaglutide and cagrilintide, showing 25% mean weight loss in women compared to 3% for placebo. While results are competitive with existing treatments like Eli Lilly's Zepbound (26% efficacy), they are not superior enough to significantly recapture market share from Eli Lilly's dominant position. The modest investor reaction suggests the drug alone may not materially improve Novo Nordisk's fortunes, though the company's broader pipeline in other therapeutic areas remains a potential catalyst.

An investment analyst discusses their strategy with Eli Lilly stock, highlighting the pharmaceutical industry's business growth and robust pipeline of new treatments. The article emphasizes the diversification benefits of pharmaceutical stocks due to their lower correlation with the broader economy.

Eli Lilly (LLY) closed at $1,240.34, down 1.33% in the latest session. The pharmaceutical giant holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 37.46, significantly above its industry average of 16.91.

While the company is expected to report 25.59% revenue growth for the upcoming quarter, EPS is anticipated to decline 23.36% year-over-year. The Large Cap Pharmaceuticals industry ranks in the bottom 15% of all industries.

Eli Lilly is expanding access to its products at lower realized prices while improving margins—an unusual combination that could strengthen further as manufacturing costs decline. The company's retatrutide drug approaches a potential 2027 filing, and investors are evaluating whether the current valuation still offers room for growth.

Regeneron Pharmaceuticals is emerging as a competitive player in the rapidly growing weight loss market with two differentiated candidates: olatorepatide, which shows better gastrointestinal tolerability than competitors with 19% mean weight loss, and trevogrumab, designed to preserve lean muscle mass alongside anti-obesity drugs. Beyond weight loss, Regeneron's strong pipeline including Dupixent and newer Eylea HD formulation positions it for medium-term growth.

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $27.7 billion in first-half 2026 sales, up 88% year-over-year, accounting for 65% of total revenues. The company's newly launched oral obesity therapy Foundayo posted $98 million in Q2 sales with expanding coverage. Lilly faces competition from Novo Nordisk's semaglutide drugs and emerging biotech firms developing alternative GLP-1 therapies.

Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments.

Ken Griffin's Citadel significantly increased positions in healthcare stocks during Q2, boosting AbbVie by 546%, Abbott Laboratories by 349%, and Eli Lilly by 291%. The moves suggest Griffin is seeking defensive, dividend-yielding stocks amid anticipated market volatility. AbbVie, a Dividend King with 54 consecutive years of dividend increases, is highlighted as a strong buy with attractive valuation and solid earnings growth.

Eli Lilly's pipeline extends beyond its blockbuster weight-loss drug Zepbound, with three promising medicines poised to drive future growth: Foundayo (oral GLP-1 for weight loss), Onswik (once-weekly basal insulin for diabetes), and retatrutide (investigational triple-hormone weight-loss drug showing 28.3% average weight loss). These drugs target different patient segments and indications, positioning Eli Lilly to maintain market leadership despite increasing competition.

A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.

The Lilly Foundation, Eli Lilly's largest shareholder with 9.6% ownership, is selling 300,000 shares worth $347 million. However, this sale is a required annual charity payout and does not reflect bearish sentiment on the stock.

Eli Lilly is leading the GLP-1 drug revolution with its tirzepatide drug (Mounjaro/Zepbound) becoming the world's best-selling drug. With Morgan Stanley forecasting the GLP-1 market to reach $190 billion by 2035 and Wall Street analysts targeting 10% upside, the article recommends buying rather than selling.

Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results.

The article recommends five diversified stocks for beginner investors with $1,000: Palantir Technologies for growth through AI, AGNC for high dividend income, Eli Lilly for healthcare exposure, SoFi for fintech innovation, and Berkshire Hathaway for stability and security. The piece emphasizes that even small initial investments can compound significantly over decades, with potential returns ranging from $2,594 to $267,864 depending on annual growth rates.

Roche has secured worldwide rights to Rona Therapeutics' investigational ALK7-targeting RNAi candidate for obesity treatment, with up to $100 million upfront and $1.06 billion in potential milestone payments. The deal strengthens Roche's metabolic disease pipeline alongside its Phase III enicepatide program, though the company faces intense competition from Eli Lilly and Novo Nordisk in the rapidly growing obesity market.